The HDAC2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the HDAC2 gene in the HAP1 near-haploid human cell line. This loss-of-function model facilitates studies of HDAC2-dependent transcriptional regulation without relying on pharmacological inhibition, providing a clean genetic approach to dissect its biological functions.
The HAP1 cell line is a near-haploid adherent fibroblastoid line derived from the male KBM-7 chronic myelogenous leukemia cell line. With a predominantly haploid karyotype, HAP1 cells are widely used in genetic screens because loss-of-function mutations yield clear, unambiguous phenotypes. Their robust growth and compatibility with high-content assays make them an ideal host for studying gene function.
HDAC2 encodes a class I histone deacetylase that deacetylates histones H3 and H4, promoting chromatin compaction and transcriptional repression. It functions in multiprotein complexes like Sin3, NuRD, and CoREST, interacting with scaffold proteins SIN3A, MTA1/2, and CoREST. HDAC2 also deacetylates transcription factors p53, E2F1, and NF-??B, modulating their activities. Upstream regulators include CK2, NICD, and the PI3K/AKT pathway, while downstream targets include CDKN1A (p21), BAX, BIM, and c-Myc, linking HDAC2 to cell cycle control and apoptosis.
In HAP1 cells, HDAC2 knockout provides a simplified genetic background to study its role in cancer-relevant pathways. The haploid nature eliminates heterozygous complications, enabling clear attribution of phenotypes. This polyclonal population is suited for synthetic lethality screens with HDAC inhibitors and mapping chromatin modifications without off-target effects, making it a valuable tool for epigenetic drug target validation.
Research applications encompass gene regulation, cancer biology (colorectal, gastric, lung), neurobiology, and cardiovascular research. Compatible assays include ChIP-qPCR for histone acetylation, RNA-seq, co-immunoprecipitation of partners like SIN3A and CHD3/4, and drug sensitivity testing with HDAC inhibitors. For further information, contact Ascent Research.
